179 related articles for article (PubMed ID: 11914909)
41. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
42. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
43. Phase II clinical evaluation of 4'-epi-doxorubicin.
Hurteloup P; Cappelaere P; Armand JP; Mathé G
Cancer Treat Rep; 1983 Apr; 67(4):337-41. PubMed ID: 6573956
[TBL] [Abstract][Full Text] [Related]
44. Weekly non-pegylated liposomal doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer.
Masci G; Gandini C; Zuradelli M; Losurdo A; Torrisi R; Rota S; Gullo G; Velutti L; Giordano L; Santoro A
Anticancer Res; 2013 Oct; 33(10):4603-9. PubMed ID: 24123037
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
[TBL] [Abstract][Full Text] [Related]
46. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.
Symon Z; Peyser A; Tzemach D; Lyass O; Sucher E; Shezen E; Gabizon A
Cancer; 1999 Jul; 86(1):72-8. PubMed ID: 10391566
[TBL] [Abstract][Full Text] [Related]
47. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
Bernardi D; Errante D; Stefani M; Salvagno L
Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
[No Abstract] [Full Text] [Related]
48. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
Ranson MR; Carmichael J; O'Byrne K; Stewart S; Smith D; Howell A
J Clin Oncol; 1997 Oct; 15(10):3185-91. PubMed ID: 9336354
[TBL] [Abstract][Full Text] [Related]
49. Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Neidhart JA; Laufman LR; Vaughn C; McCracken JD
Cancer Treat Rep; 1980; 64(4-5):675-7. PubMed ID: 7427953
[TBL] [Abstract][Full Text] [Related]
50. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
51. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
52. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
[TBL] [Abstract][Full Text] [Related]
53. Phase I trial of aclacinomycin A.
Van Echo DA; Whitacre MY; Aisner J; Applefeld MM; Wiernik PH
Cancer Treat Rep; 1982 May; 66(5):1127-32. PubMed ID: 6952961
[TBL] [Abstract][Full Text] [Related]
54. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Rivera E; Valero V; Syrewicz L; Rahman Z; Esteva FJ; Theriault RL; Rosales MM; Booser D; Murray JL; Bast RC; Hortobagyi GN
J Clin Oncol; 2001 Mar; 19(6):1716-22. PubMed ID: 11251001
[TBL] [Abstract][Full Text] [Related]
55. Effect of long-term music therapy intervention on autonomic function in anthracycline-treated breast cancer patients.
Chuang CY; Han WR; Li PC; Song MY; Young ST
Integr Cancer Ther; 2011 Dec; 10(4):312-6. PubMed ID: 21382955
[TBL] [Abstract][Full Text] [Related]
56. Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience.
Perez AT; Domenech GH; Frankel C; Vogel CL
Cancer Invest; 2002; 20 Suppl 2():22-9. PubMed ID: 12442346
[TBL] [Abstract][Full Text] [Related]
57. Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer.
Cummings FJ; Gelman R; Tormey DC; DeWys W; Glick J
Cancer Clin Trials; 1981; 4(3):253-60. PubMed ID: 7026074
[TBL] [Abstract][Full Text] [Related]
58. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
59. Kaposi's sarcoma: DaunoXome approved.
AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485
[TBL] [Abstract][Full Text] [Related]
60. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Ibrahim NK; Hortobagyi GN; Ewer M; Ali MK; Asmar L; Theriault RL; Fraschini G; Frye DK; Buzdar AU
Cancer Chemother Pharmacol; 1999; 43(6):471-8. PubMed ID: 10321507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]